Used in the treatment of systemic lupus erythematosus (SLE), this antibody targets and inhibits the activity of B-cell activating factor (BAFF), reducing the survival of autoreactive B cells. By blocking BAFF, it helps decrease disease activity, reduce flare-ups, and lower the need for high-dose corticosteroids in patients with active, autoantibody-positive SLE. It is administered intravenously and is particularly effective in patients who have not responded adequately to standard therapies. Its use is associated with improved long-term outcomes and a favorable safety profile in carefully selected patients.